title: Efficacy and clinical cross-resistance of a new combination therapy (AMSA/VP16) in previously treated patients with acute nonlymphocytic leukemia.
abstract: We investigated the tolerance, efficacy, and clinical cross-resistance of a new combination chemotherapy in 38 patients with previously treated acute myeloblastic leukemia (AML). It consisted of 120 mg2/d 4'(9-acridinylamino) methanesulfon-m-Anisidide (m-AMSA) in a one-hour infusion and 80 mg/m2/d etoposide (VP-16) in a 24-hour infusion, both administered for 5 days. The first 27 patients also received vinblastine, 6 mg/m2 on day 8, but this therapy was discontinued because of intestinal complications. Thirteen of 23 patients (56%) at first or subsequent relapse and five of 15 patients (33%) who were primarily resistant to an anthracycline/cytarabine combination achieved a complete response (CR) (hemoglobin level not taken into account) with a median CR duration of 5 months and 2 months, respectively. The response rate was as high as 63% for patients at first or second relapse whether the remission was maintained or not. The median times to recovery of normal bone marrow cellularity, of blood granulocyte counts greater than 500/microL, and of platelets greater than 20,000/microL were 34, 27, and 22 days, respectively. Marked but reversible gastrointestinal toxicity was observed in 24% of the patients, and two patients died of infection during induction. The one-hour AMSA/continuous VP-16 combination is effective for patients with relapsing AML and shows no cross-resistance in a proportion of patients refractory to the standard anthracycline-cytarabine combination.
authors.forename: L
authors.initials: L
authors.lastname: Tschopp
authors.forename: V E
authors.initials: VE
authors.lastname: von Fliedner
authors.forename: C
authors.initials: C
authors.lastname: Sauter
authors.forename: P
authors.initials: P
authors.lastname: Maurice
authors.forename: A
authors.initials: A
authors.lastname: Gratwohl
authors.forename: M
authors.initials: M
authors.lastname: Fopp
authors.forename: F
authors.initials: F
authors.lastname: Cavalli
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000609:Aminoacridines / Q000008:administration & dosage / Q000009:adverse effects; D000677:Amsacrine; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001853:Bone Marrow / Q000187:drug effects; D004351:Drug Resistance; D005047:Etoposide / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D010976:Platelet Count / Q000187:drug effects
chemical_list: D000609:Aminoacridines; D000677:Amsacrine; D005047:Etoposide